Galapagos NV Stock Euronext Bruxelles
Equities
GLPG
BE0003818359
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.1 EUR | 0.00% | 0.00% | 0.00% |
Sales 2024 * | 313M 340M | Sales 2025 * | 302M 328M | Capitalization | 1.69B 1.84B |
---|---|---|---|---|---|
Net income 2024 * | -13M -14.11M | Net income 2025 * | -71M -77.09M | EV / Sales 2024 * | -5.35 x |
Net cash position 2024 * | 3.37B 3.66B | Net cash position 2025 * | 2.97B 3.23B | EV / Sales 2025 * | -4.23 x |
P/E ratio 2024 * |
-43.7
x | P/E ratio 2025 * |
-16.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.64% |
Latest transcript on Galapagos NV
Managers | Title | Age | Since |
---|---|---|---|
Paulus Stoffels
CEO | Chief Executive Officer | 62 | 22-03-31 |
Thad Huston
DFI | Director of Finance/CFO | 54 | 23-05-31 |
Investor Relations Contact | - | 20-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Dickinson
BRD | Director/Board Member | 54 | Mar. 26 |
Jérôme Contamine
BRD | Director/Board Member | 66 | 22-04-25 |
Simon Sturge
BRD | Director/Board Member | 65 | 23-09-18 |
1st Jan change | Capi. | |
---|---|---|
+69.84% | 62.86B | |
-0.99% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+14.36% | 26.46B | |
-21.81% | 18.9B | |
+4.35% | 12.67B | |
+23.98% | 12.27B | |
+28.96% | 12.07B |
- Stock Market
- Equities
- GLPG Stock
- GLPG Stock